ArticleVeterinary medicine (Auckland, N.Z.)2024
Efficacy of Vaccination with the DIVENCE
Article in Veterinary medicine (Auckland, N.Z.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- A novel bovine viral vaccine for reproductive safety and performance in cattle.Frontiers in veterinary science · 2026Article
- Therapeutic efficacy of bovine ultra-long CDR H3 antibody against BVDV in challenged BALB/c mouse model.Frontiers in immunology · 2026Article
- Novel BPI3Vc-vectored chimeric BVDV antigens elicit broadly neutralizing antibodies in cattle.Frontiers in immunology · 2026Article
- Article
- Immunological responses against bovine viral diarrhoea virus types 1 and 2 after administration of a commercial subunit vaccine measured by ELISA and serum neutralisation on serum and milk samples.Veterinary record open · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To demonstrate the efficacy of DIVENCE Materials and Methods: Calves of two-to-three months of age were given two intramuscular doses three weeks apart and a booster vaccine six months later. Efficacy was evaluated by means of a challenge with virulent BVDV-1 or BVDV-2 administered via the intranasal route at 85 days of gestation. Clinical signs, serology, viral shedding, WBC count and viremia were monitored after the challenge. Sixty-six days post-challenge, the fetuses were assessed for BVDV to detect transplacental infection. Results: Vaccinated animals showed a significant ( Conclusion: DIVENCE
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.